Latest Period
Q1 2026
Security Snapshot
Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS) Institutional Ownership
CUSIP: 747324101
13F Institutional Holders and Ownership History from Q4 2021 to Q1 2026
Institutions Reporting
76
Shares (Excl. Options)
27,372,838
Price
$1.46
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- PYXS on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 27,372,838
- Total 13F value
- $38,908,028
- Portfolio coverage rank
- 0%
- Share change
- -2,203,104
- Value change
- -$2,992,961
- Number of holders
- 76
- Shares outstanding
- 62,130,557
- SEC-reported price per share
- $2.26
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- PYXS - Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 747324101.
- 76 institutions reported positions in Q1 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 78 to 76 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $34,729,768 to $38,908,028.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 76 institutions filings for Q1 2026.
Security key
747324101
Latest holder period
Q1 2026
13F holders
76
13D/G owners
7
CIK / CUSIP context first
Open Q1 2026 holders
PYXS full holder history
Pyxis Oncology, Inc. SEC filings
Pyxis Oncology, Inc. company facts
Pyxis Oncology, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 747324101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
PYXS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Sullivan Lara | 11% | +9.1% | $7,844,727 | +$955,040 | 7,543,007 | +14% | Lara Sullivan, M.D. | 31 Mar 2025 |
| Laurion Capital Management LP | 7.7% | $9,880,747 | 4,796,479 | Laurion Capital Management LP | 31 Dec 2025 | |||
| GordonMD Global Investments LP | 6.2% | $5,330,289 | 3,834,740 | GordonMD Global Investments LP | 14 Jul 2025 | |||
| INTEGRATED CORE STRATEGIES (US) LLC | 4% | -26% | $2,587,602 | -$698,942 | 2,488,079 | -21% | Millennium Management LLC | 31 Mar 2025 |
| BlackRock, Inc. | 1.5% | -68% | $2,192,635 | -$5,718,934 | 926,805 | -72% | BlackRock, Inc. | 30 Jun 2025 |
| MILLENNIUM MANAGEMENT LLC | 1.3% | -73% | $1,497,185 | -$4,985,888 | 818,134 | -77% | Millennium Management LLC | 30 Sep 2025 |
| Ridgeback Capital Investments L.P. | 0.6% | $373,600 | 359,231 | Ridgeback Capital Investments L.P. | 31 Dec 2024 |
As of 31 Mar 2026, 76 institutional investors reported holding 27,372,838 shares of Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS). This represents 44% of the company’s total 62,130,557 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
42%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Pfizer Inc | 11% | 7,032,770 | 0% | 3.9% | $9,212,929 |
| Laurion Capital Management LP | 8% | 4,997,333 | +4.2% | 0.68% | $7,296,106 |
| GordonMD Global Investments LP | 6.6% | 4,121,870 | 0% | 5.2% | $6,017,930 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.3% | 2,033,510 | 0% | 0% | $2,968,925 |
| Palo Alto Investors LP | 1.6% | 1,010,510 | -2.6% | 0.23% | $1,475,345 |
| 683 Capital Management, LLC | 1.4% | 896,263 | +0.49% | 0.12% | $1,308,544 |
| RENAISSANCE TECHNOLOGIES LLC | 1.4% | 888,680 | +22% | 0% | $1,297,473 |
| BlackRock, Inc. | 1.3% | 788,839 | +0.61% | 0% | $1,151,705 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.96% | 598,121 | +3.6% | 0% | $873,815 |
| Longaeva Partners L.P. | 0.81% | 503,214 | 0% | 0.04% | $734,692 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0.74% | 460,997 | 0% | $673,056 | |
| MILLENNIUM MANAGEMENT LLC | 0.64% | 397,625 | -46% | 0% | $580,533 |
| MARSHALL WACE, LLP | 0.57% | 354,417 | -9.1% | 0% | $517,448 |
| Decheng Capital LLC | 0.53% | 326,810 | 0% | 0.07% | $477,143 |
| JANE STREET GROUP, LLC | 0.49% | 304,459 | -61% | 0% | $444,510 |
| VANGUARD FIDUCIARY TRUST CO | 0.48% | 300,897 | 0% | 0% | $439,310 |
| UBS Group AG | 0.41% | 254,124 | -35% | 0% | $371,021 |
| STATE STREET CORP | 0.4% | 248,837 | +3% | 0% | $363,302 |
| XTX Topco Ltd | 0.32% | 200,096 | -31% | 0.01% | $292,140 |
| ACADIAN ASSET MANAGEMENT LLC | 0.23% | 144,256 | 0% | $209,000 | |
| Bank of New York Mellon Corp | 0.22% | 133,996 | -19% | 0% | $195,634 |
| NewEdge Wealth, LLC | 0.19% | 116,006 | 0% | 0% | $169,369 |
| NORTHERN TRUST CORP | 0.16% | 101,948 | 0% | 0% | $148,844 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.13% | 81,260 | +12% | 0% | $118,640 |
| TWO SIGMA INVESTMENTS, LP | 0.12% | 73,300 | -31% | 0% | $107,018 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
18
Latest
Q1 2026
Rows shown
1-18 of 18
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 27,372,838 | $38,908,028 | -$2,992,961 | $1.46 | 76 |
| 2025 Q4 | 30,195,945 | $34,729,768 | -$6,939,019 | $1.15 | 78 |
| 2025 Q3 | 26,713,589 | $59,287,871 | +$123,860 | $2.22 | 72 |
| 2025 Q2 | 27,457,764 | $30,197,446 | -$2,879,012 | $1.10 | 74 |
| 2025 Q1 | 30,249,732 | $29,641,653 | -$2,654,672 | $0.98 | 88 |
| 2024 Q4 | 31,554,509 | $49,227,444 | -$20,797,470 | $1.56 | 97 |
| 2024 Q3 | 27,885,908 | $103,378,553 | -$998,440 | $3.67 | 91 |
| 2024 Q2 | 28,117,599 | $93,075,160 | +$16,220,879 | $3.31 | 78 |
| 2024 Q1 | 22,927,678 | $97,671,130 | +$61,948,310 | $4.26 | 69 |
| 2023 Q4 | 8,795,542 | $15,830,945 | +$874,420 | $1.80 | 50 |
| 2023 Q3 | 7,757,315 | $15,436,473 | -$3,354,663 | $1.99 | 49 |
| 2023 Q2 | 9,605,170 | $24,586,580 | -$3,344,692 | $2.56 | 46 |
| 2023 Q1 | 10,344,999 | $41,482,052 | -$20,570,227 | $4.01 | 46 |
| 2022 Q4 | 19,762,209 | $26,479,807 | -$1,331,635 | $1.34 | 31 |
| 2022 Q3 | 19,443,728 | $38,301,000 | -$1,468,358 | $1.97 | 35 |
| 2022 Q2 | 20,034,321 | $47,682,000 | -$658,113 | $2.38 | 37 |
| 2022 Q1 | 18,945,997 | $76,067,000 | -$5,559,229 | $4.04 | 44 |
| 2021 Q4 | 18,338,628 | $199,903,000 | +$199,792,959 | $10.97 | 51 |